Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis Patients

Summary

This is a two-period, two-sequence crossover study in patients receiving maintenance peritoneal dialysis. All participants remain on background darbepoetin alfa therapy throughout the study. The study compares add-on vadadustat plus background darbepoetin alfa with background darbepoetin alfa alone, with each treatment period lasting 8 weeks and separated by a 4-week washout period. Monthly laboratory assessments and dialysis adequacy measurements will be performed to evaluate anemia control, quality of life, inflammation, and dialysis adequacy.

Timeline

Start

2026-04-15

Primary completion

2026-09-30

Completion

2026-10-15

Drugs

Indications